Important (US-only, investigational): Retatrutide (also called LY3437943) is investigational in the United States. That means it is being studied in clinical trials and is not FDA-approved for weight loss, diabetes, fatty liver disease, or any other condition as of this writing. This article is for education and does not replace medical advice.
Short answer
Retatrutide is a once-weekly injectable medicine being studied for obesity and metabolic disease that activates three hormone receptors at the same time:
- GLP-1 receptor
- GIP receptor
- Glucagon receptor
In simple terms, retatrutide is designed to:
- Lower appetite and increase fullness
- Improve blood-sugar control
- Potentially increase energy expenditure (an effect linked to glucagon signaling)
That “three-lever” approach is why retatrutide is often described as a triple agonist, and why it has produced large average weight loss in phase 2 studies.
What is retatrutide, exactly?
Retatrutide is a single molecule that can bind to and activate three different receptors:
- GLP-1 (glucagon-like peptide-1)
- GIP (glucose-dependent insulinotropic polypeptide)
- Glucagon
These hormones are part of the body’s meal-response system: appetite, insulin release, stomach emptying, and how the body uses energy.
A quick vocabulary guide
- Agonist: activates a receptor.
- Receptor: a docking site on cells that triggers downstream effects.
- Incretins: gut hormones (especially GLP-1 and GIP) that help manage glucose after meals.
Why “triple agonist” matters: a patient-friendly framework
Many currently available medicines target one pathway (GLP-1). Some newer medicines target two (GLP-1 + GIP). Retatrutide targets three (GLP-1 + GIP + glucagon).
A simple mental model:
- GLP-1: fullness + slower stomach emptying + better glucose handling
- GIP: supports meal-time insulin response; complex effects in fat tissue
- Glucagon: mobilizes stored fuel and may increase energy expenditure (with glucose caveats)
GLP-1: fullness signals and GI side effects
GLP-1 activation often reduces appetite and “food noise,” but is also linked to common side effects: nausea, vomiting, diarrhea/constipation, reflux.
GIP: complement to GLP-1 (especially for glucose)
GIP is another incretin that can complement GLP-1’s glucose effects and may modify tolerability for some people.
Glucagon: energy expenditure (and why it’s paired)
Glucagon can raise blood glucose in classic physiology, but in multi-agonist designs it may contribute to energy expenditure. Pairing with incretin effects is part of the design to balance glucose control.
What phase 2 trials have shown (high level)
- Obesity phase 2 (NEJM 2023): substantial average weight loss in study conditions.
- Type 2 diabetes phase 2 (Lancet 2023): glucose improvements plus weight loss.
Myths and misconceptions
- Myth: triple agonist = three drugs mixed together.
More accurate: one molecule that activates three receptors. - Myth: phase 2 means “basically approved.”
More accurate: phase 3 + FDA review are still required. - Myth: buy “research peptides” online.
More accurate: high risk; safest route is regulated clinical trials.
References
- Retatrutide phase 2 obesity trial (PubMed): https://pubmed.ncbi.nlm.nih.gov/37366315/
- Retatrutide phase 2 type 2 diabetes trial (PubMed): https://pubmed.ncbi.nlm.nih.gov/37385280/
- MedlinePlus: Glucagon blood test (background): https://medlineplus.gov/lab-tests/glucagon-blood-test/
- NCBI Bookshelf: GLP-1 receptor agonists (background): https://www.ncbi.nlm.nih.gov/books/NBK551568/